Squamous Cell Carcinoma of Head and Neck

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2022-02-08
Clinical Trial Update: Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck [Phase 2, Phase 3]
A clinical trial investigating enoblituzumab with MGA012 or MGD013 in squamous cell carcinoma of the head and neck has been withdrawn.